Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.31 M USD
0.00 USD
3.76 M
About Altamira Therapeutics Ltd.
Sector
Industry
CEO
Thomas Meyer
Website
Headquarters
Hamilton
Founded
2003
FIGI
BBG006R5ZLT9
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CYTO is 0.4230 USD — it has decreased by −3.31% in the past 24 hours. Watch Altamira Therapeutics Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Altamira Therapeutics Ltd. stocks are traded under the ticker CYTO.
CYTO stock has fallen by −3.86% compared to the previous week, the month change is a −24.46% fall, over the last year Altamira Therapeutics Ltd. has showed a −93.62% decrease.
CYTO reached its all-time high on Jan 6, 2016 with the price of 3,184.0000 USD, and its all-time low was 0.4000 USD and was reached on Nov 13, 2024. View more price dynamics on CYTO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CYTO stock is 12.77% volatile and has beta coefficient of 0.33. Track Altamira Therapeutics Ltd. stock price on the chart and check out the list of the most volatile stocks — is Altamira Therapeutics Ltd. there?
Today Altamira Therapeutics Ltd. has the market capitalization of 1.60 M, it has decreased by −3.93% over the last week.
Yes, you can track Altamira Therapeutics Ltd. financials in yearly and quarterly reports right on TradingView.
Altamira Therapeutics Ltd. is going to release the next earnings report on Apr 9, 2025. Keep track of upcoming events with our Earnings Calendar.
CYTO earnings for the last half-year are −1.99 USD per share, whereas the estimation was −2.38 USD, resulting in a 16.60% surprise. The estimated earnings for the next half-year are −0.57 USD per share. See more details about Altamira Therapeutics Ltd. earnings.
Altamira Therapeutics Ltd. revenue for the last half-year amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next half-year.
CYTO net income for the last half-year is −4.34 M USD, while the previous report showed −5.94 M USD of net income which accounts for 26.99% change. Track more Altamira Therapeutics Ltd. financial stats to get the full picture.
No, CYTO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 12.00 employees. See our rating of the largest employees — is Altamira Therapeutics Ltd. on this list?
Like other stocks, CYTO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Altamira Therapeutics Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Altamira Therapeutics Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Altamira Therapeutics Ltd. stock shows the sell signal. See more of Altamira Therapeutics Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.